UK Regulator Issues Guidance for Non-OECD Clinical Trial Data Assessment

The UK's MHRA has released new guidance on evaluating non-clinical safety data from outside the OECD Mutual Acceptance of Data framework for clinical trial applications. This patient-centered approach aims to streamline clinical research with a risk-proportionate method. The initiative seeks to accelerate the development of new treatments and increase opportunities for UK patients to participate in trials, potentially impacting drug development timelines.